by Andrea Lobo | Mar 12, 2026 | Myeloma News
Inovio Pharmaceuticals and Akeso have entered into a clinical trial collaboration and supply agreement to evaluate a novel immunotherapy combining INO-5412 plus cadonilimab as a potential treatment for glioblastoma, an aggressive form of glioma. The Phase 2 INSIGhT...
by Marisa Wexler, MS | Mar 11, 2026 | Myeloma News
A combination of two immune-modulating treatments, Lymphir (denileukin diftitox) and Keytruda (pembrolizumab), was well tolerated in an exploratory clinical trial of people with hard-to-treat gynecological cancers. The Phase 1/2 study (NCT05200559) is sponsored by...
by MM360 Staff | Mar 11, 2026 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by Marisa Wexler, MS | Mar 10, 2026 | Myeloma News
The U.S. Food and Drug Administration (FDA) has approved the combination of Tecvayli (teclistamab) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) for treating certain people with multiple myeloma. The approval specifically covers myeloma patients whose...
by MM360 Staff | Mar 10, 2026 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by Marisa Wexler, MS | Mar 9, 2026 | Myeloma News
Treatment with the targeted therapy Venclexta (venetoclax) in combination with chemotherapy led to disease remission for most people with hard-to-treat acute myeloid leukemia (AML) in an early clinical trial, with most patients able to undergo stem cell transplant...
